CytoMed Historical Valuation
| GDTC Stock | 2.61 0.05 1.88% |
Some fundamental drivers such as market cap or CytoMed Therapeutics enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze CytoMed Therapeutics valuation indicators such as to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of CytoMed Therapeutics's future value.
CytoMed Therapeutics Working Capital |
|
CytoMed |
About CytoMed Valuation Data Analysis
Valuation is the financial process of determining what CytoMed Therapeutics is worth. CytoMed Therapeutics valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. CytoMed Therapeutics valuation ratios help investors to determine whether CytoMed Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CytoMed with respect to the benefits of owning CytoMed Therapeutics security.
CytoMed Therapeutics Valuation Data Chart
Enterprise Value
Enterprise Value (or EV) is usually referred to as CytoMed Therapeutics theoretical takeover price. In the event of an acquisition, an acquirer would have to take on CytoMed Therapeutics debt, but would also pocket its cash. Enterprise Value is more accurate representation of CytoMed Therapeutics value than its market capitalization because it takes into account all of CytoMed Therapeutics Limited existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.Most indicators from CytoMed Therapeutics' valuation accounts are interrelated and interconnected. However, analyzing valuation accounts indicators one by one will only give a small insight into CytoMed Therapeutics current financial condition. On the other hand, looking into the entire matrix of valuation accounts indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. The current year's Working Capital is expected to grow to about (1.4 M). In addition to that, Enterprise Value is expected to decline to about 24.5 M
CytoMed Therapeutics valuation accounts Correlations
CytoMed Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CytoMed Therapeutics valuation accounts Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 25.2M | 28.3M | 33.6M | 43.5M | 39.2M | 24.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share | Quarterly Revenue Growth (0.21) | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.